Browse > Article
http://dx.doi.org/10.14374/HFS.2014.22.1.167

Comparison of Gangjihwan and Combination of Gangjihwan and Gamisochehwan in the Improvement Effects of Nonalcoholic Fatty Liver Disease in a High Fat Diet-Fed NAFLD Mouse Model  

Jang, Du Hyon (Chungnam Korean Medicine Clinic)
Jung, Yang Sam (Jungyangsam Korean Medicine Clinic)
Kim, Jong Hoon (Neungin Korean Medicine Clinic)
Kim, Byeong Chul (Goryo Korean Medicine Clinic)
Seok, Hoa Jun (Soojung Korean Medicine Clinic)
Yoo, Jae Sang (Bonghwang Korean Medicine Clinic)
Ku, Ja Ryong (Soricheong Luck Korean Medicine Clinic)
Yoon, Ki Hyeon (Dept. of Formula Sciences and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dong-Eui University)
Jo, Ju Heum (Woosim Korean Medicine Clinic)
Lee, Hye Rim (Dept. of Formula Sciences and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dong-Eui University)
Roh, Jong Seong (Dept. of Formula Sciences and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dong-Eui University)
Yun, Ho Young (Dept. of Formula Sciences and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dong-Eui University)
Yoon, Michung (Dept. of Life Sciences, Mok-Won University)
Shin, Soon Shik (Dept. of Formula Sciences and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dong-Eui University)
Publication Information
Herbal Formula Science / v.22, no.1, 2014 , pp. 167-176 More about this Journal
Abstract
Objectives : This study investigated the improvement effects of Gangjihwan (DF) and combination of Gangjihwan and Gamisochehwan (GSH) on nonalcoholic fatty liver disease in a high fat diet-induced obese mouse model. Methods : Eight-week-old C57BL/6N mice were divided into five groups: a normal lean group given a standard diet, an obese control group given a high fat diet, and atorvastatin, DF, and DF+GSH groups given a high fat diet with atorvastatin (10 mg/kg), DF (40 mg/kg), and DF+GSH (80 mg/kg), respectively. After 8 weeks of treatment, body weight gain, blood lipid markers, ALT concentrations, liver weight and histology were examined. Results : 1. Body weight gain was significantly decreased in DF, DF+GSH and atorvastatin groups compared with control. The extent of decreases was eminent in DF+GSH group. 2. Circulating concentrations of total cholesterol, HDL-cholesterol and LDL-cholesterol were decreased in DF, DF+GSH and atorvastatin groups compared with control. The decreases were significant in DF+GSH and atorvastatin groups. 3. Liver weights were decreased in DF, DF+GSH and atorvastatin groups compared with control. In particular, liver weight was significantly reduced only in DF+GSH group. 4. Hepatic lipid accumulation was significantly decreased in DF, DF+GSH and atorvastatin groups compared with control, and the magnitude of which was more effective in DF+GSH group than in DF-only group. 5. Circulating ALT concentrations were decreased in DF, DF+GSH and atorvastatin compared with control, but ALS levels were significantly reduced only in DF+GSH group. Conclusions : In conclusion, these results suggest that DF decreases body weight gain, improves blood lipid metabolism, and reduces liver weight and hepatic lipid accumulation, contributing to the improvement of nonalcoholic fatty liver disease. In addition, these effects were more effective in DF+GSH combination group than in DF-only group.
Keywords
Gangjihwan; nonalcoholic fatty liver disease; Gamisochehwan; ALT; cholesterol;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Kim TK, Jung WS, Park SW, Cho KH, Kim YS. Comparison of efficacy and safety between Chunghyul-dan(HH-333) and Atorvastatin(Lipitor$^{(R)}$). Kor J of Orient Int Med. 2003; 24(4): 837-845.
2 Prineas RJ, Folsom AR, Kaye SA. Central adiposity and increased risk of coronary artery disease mortality in older women. Ann Epidermiol. 1993; 3: 35-41.   DOI   ScienceOn
3 Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci, 1995; 10: 414-421.   과학기술학회마을   DOI
4 Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004; 53: 413-419.   DOI   ScienceOn
5 Park KS, Jang BK, Kwon KM, Chung WJ, Cho KB, Hwang JS, Ahn SH, Mun KC, Kim YH. Antioxidant status in nonalcoholic steatohepatitis. Korea J Hepatol. 2005; 11(2): 135-143.   과학기술학회마을
6 Day CP, James OF. Steatohepatitis: a tale of two "hits"?. Gastroenterol. 1998; 114: 842-845.   DOI   ScienceOn
7 Durazzo M, Belci P, Collo A, Grisoglio E, Bo S. Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease. Int J Hepatol. 2012; 2012: 464706.
8 Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221-229.   DOI   ScienceOn
9 Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.   DOI
10 Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.   DOI
11 Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J of Hepatol. 2005; 42(1): 132-138.
12 Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes. 2001; 50: 1844-1850.   DOI   ScienceOn
13 MGaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5: 1544-1560.   DOI
14 National Institute of Food and Drug Safety Evaluation. Influence of dietary intake on non-alcoholic fatty liver disease in Korean. 2012: 1.
15 Reynoso E, Lavine JE. NAFLD: The role of exercise in treating NAFLD. Nat Rev Gastroenterol and Hepatol. 2012; 9: 368-370.   DOI
16 Ye Ji Ahn, Ki Hyeon Yoon, Ju Heum Jo, Du Hyon Jang, Yang Sam Jung, Jong Hoon Kim, Byeong Chul Kim, Hoa Jun Seok, Jae Sang Yoo, Ja Ryong Ku, Michung Yoon, Soon Shik Shin. Gangjihwan Improves Nonalcoholic Fatty Liver Disease in High Fat Diet-Fed C57BL/6N Mice. Kor. J. Herbology 2014; 29(2): 47-54.   과학기술학회마을   DOI   ScienceOn
17 Yun Gil Yeong. Clinical Formula Science of Korean Medicine. Seoul: Myeongbo Press, 1985: 387.